皮膚科臨床アセット　11　シミと白斑　最新診療ガイド

出版社： 中山書店
著者：
発行日： 2012-10-10
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784521733487
シリーズ： 皮膚科臨床アセット
電子書籍版： 2012-10-10 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

商品紹介

シミや白斑のほとんどは，生命を脅かすものではないが，疾患として目立つため患者のQOLには大きな障害を及ぼす。本書ではシミや白斑の病態について，新知見を含め詳述。また鑑別診断に重点を置き，それぞれの疾患に応じた治療の組み立て方を解説．外用薬や内服療法，レーザー治療，外科的治療，そして最新の美白剤や抗酸化療法さらに化粧品によるカモフラージュまで網羅。これからの皮膚科医必携の一冊。

目次

  • 皮膚科臨床アセット　11　シミと白斑　最新診療ガイド

    ―目次―

    I　シミ
    　●総論
    　　1　シミの定義と頻度・性差・好発年齢
    　　2　シミ疾患の病態と診断
    　　3　シミの鑑別診断
    　　4　メラニン生成機序：最新の理解
    　　5　ユーメラニンの生理的役割
    　　6　フェオメラニンの役割はどこまで明らかになっているか
    　　7　シミの治療に欠かせない基礎知識
    　　8　シミの予防と治療（１）：保健医療
    　　9　シミの予防と治療（２）：美白剤はどこまで有用か
    　　10　シミの予防と治療（３）：サプリメントはどこまで有用か
    　　11　わたしの勧めるシミ対策（１）：皮膚科の立場から
    　　12　わたしの勧めるシミ対策（２）：形成外科の立場から
    　●各論
    　　13　老人性色素斑の病態・診断・鑑別診断
    　　14　肝斑の病態・診断・鑑別診断
    　　15　雀卵斑の病態・診断・鑑別診断
    　　16　太田母斑の病態・診断・鑑別診断
    　　17　対称性真皮メラノサイトーシスの診断・鑑別診断・発症機序
    　　18　炎症後色素沈着の発症機序と診断
    　　19　薬剤性色素沈着症の発症機序と診断
    　　20　フリクションメラノーシスの発症機序と診断
    　　21　代謝異常による色素異常症
    　　22　von Recklinghausen病
    　　23　Peutz-Jeghers症候群
    　　24　遺伝性対側性色素異常症の発症機序と診断
    　　25　LEOPARD症候群の病態・診断・鑑別診断
    　　26　Cole-Engman症候群
    　　27　色素性乾皮症の病態・診断・鑑別診断
    　●シミに関する最新研究からのインサイト
    　　28　紫外線によるメラニン合成：UVBとUVAの作用機序
    　　29　美白剤の最近の動向
    　　30　抗酸化剤の美白効果
    　　31　新しいシミ治療を展望する：形成外科の立場から

    II　白斑
    　●総論
    　　32　白斑の定義と頻度
    　　33　白斑の病態と診断
    　　34　白斑の鑑別診断
    　　35　加齢と白斑
    　　36　自己免疫疾患と白斑
    　　37　白斑と遺伝性疾患
    　　38　白斑の治療方針とその決定法（指針）
    　　39　白斑の治療（１）：外用薬
    　　40　白斑の治療（２）：免疫抑制
    　　41　白斑の治療（３）：自己細胞の利用
    　　42　小児白斑の治療
    　　43　尋常性白斑の光線療法
    　　44　白斑のレーザー治療
    　　45　尋常性白斑に対するLLLT
    　　46　白斑治療におけるメイクアップの意義と方法
    　●各論
    　　47　尋常性白斑の病態・診断・鑑別診断
    　　48　薬剤・化学物質による白斑の病態・診断・鑑別診断
    　　49　Sutton白斑の病態・診断・鑑別診断
    　　50　メラノーマに伴う白斑の病態・診断・鑑別診断
    　●白斑に関する最新研究からのインサイト
    　　51　幹細胞と白斑
    　　52　抗酸化療法は白斑治療に有用か
    　　53　活性型ビタミンD３と紫外線照射併用療法の
    　　　　　白斑への治療応用

    付録　シミ・白斑のメーキャップ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I シミ

P.2 掲載の参考文献
1) 渡辺晋一. シミ・ソバカスの実態. 香粧会誌 2000 ; 24 : 287-95.
 
P.6 掲載の参考文献
1) Kang WH, Yoon KH, Lee ES, et al. Melasma : histopathological characteristics in 56 Korean patients. Br J Dermatol 2002 ; 146 : 228-37.
PubMed
2) 肥田野信, 加島英男. 両側性太田母斑. 皮膚臨床 1965 ; 7 : 72-81.
 
3) Hori Y, Kawashima M, Oohara K, et al. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984 ; 10 : 961-4.
PubMed
4) 荻野篤彦. 女子顔面黒皮症と誤れる両側性太田母斑. 臨皮 1982 ; 36 : 875-8.
 
5) 原田昭太郎, 新妻忠. 顔の色素沈着 対称型太田母斑. 皮膚病診療 1982 ; 4 : 727-30.
 
6) Sun CC, Lu YC, Lee EF, et al. Naevus fusco-caeruleus zygomaticus. Br J Dermatol 1987 ; 117 : 545-53.
PubMed
7) Watanabe S, Nakai K, Ohnishi T. Condition known as 'dark rings under the eyes' in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg 2006 ; 32 : 785-9.
PubMed
8) Turnbull JR, Assaf Ch, Zouboulis C, et al. Bilateral naevus of Ota : a rare manifestation in a Caucasian. J Eur Acad Dermatol Venereol 2004 ; 18 : 353-5.
 
P.11 掲載の参考文献
1) 肥田野信. 太田母斑. 久木田淳, ほか編. 現代皮膚科学大系 11. メラノサイト系腫瘍 母斑・母斑症. 東京 : 中山書店 ; 1982. pp191-203.
 
2) Hori Y, Kawashima M, Oohara K, et al. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984 ; 10 : 961-4.
PubMed
3) Sun CC, Lu YC, Lee EF, et al. Naevus fusco-caeruleus zygomaticus. Br J Dermatol 1987 ; 117 : 545-53.
PubMed
4) 荻野篤彦. 女子顔面黒皮症と誤れる両側性太田母斑. 臨皮 1982 ; 36 : 875-8.
 
5) 原田昭太郎, 新妻忠. 顔の色素沈着 対称型太田母斑. 皮膚病診療 1982 ; 4 : 727-30.
 
6) Watanabe S, Nakai K, Ohnishi T. Condition known as 'dark rings under the eyes' in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg 2006 ; 32 : 785-9.
PubMed
7) Turnbull JR, Assaf Ch, Zouboulis C, et al. Bilateral naevus of Ota : a rare manifestation in a Caucasian. J Eur Acad Dermatol Venereol 2004 ; 18 : 353-5.
 
P.14 掲載の参考文献
1) Park HY, Kosmadaki M, Yaar M, et al. Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 2009 ; 66 : 1493-506.
PubMed
2) Furumura M, Sakai C, Abdel-Malek Z, et al. The interaction of agouti signal protein and melanocyte stimulating hormone to regulate melanin formation in mammals. Pigment Cell Res 1996 ; 9 : 191-203.
PubMed
3) Kondo T, Hearing VJ. Update on the regulation of mammalian melanocyte function and skin pigmentation. Expert Rev Dermatol 2011 ; 6 : 97-108.
PubMed
4) Yamaguchi Y, Hearing VJ. Physiological factors that regulate skin pigmentation. Biofactors 2009 ; 35 : 193-9.
PubMed
5) Liu JJ, Fisher DE. Lighting a path to pigmentation : mechanisms of MITF induction by UV. Pigment Cell Melanoma Res 2010 ; 23 : 741-5.
PubMed
6) Gillbro JM, Olsson MJ. The melanogenesis and mechanisms of skin-lightening agents-existing and new approaches. Int J Cosmet Sci 2011 ; 33 : 210-21.
PubMed
P.23 掲載の参考文献
1) Tadokoro T, Kobayashi N, Zmudzka BZ, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. FASEB J 2003 ; 17 : 1177-9.
PubMed
1) Hearing VJ, Leong SPL, editors. From Melanocytes to Melanoma : The Progression to Malignancy. Totowa : Humana Press ; 2006.
 
2) Tadokoro T, Yamaguchi Y, Batzer J, et al. Mechanisms of skin tanning in different racial/ethnic groups in response to ultraviolet radiation. J Invest Dermatol 2005 ; 124 : 1326-32.
PubMed
3) Coelho SG, Choi W, Brenner M, et al. Short- and long-term effects of UV radiation on the pigmentation of human skin. J Investig Dermatol Symp Proc 2009 ; 14 : 32-5.
 
4) Meredith P, Sarna T. The physical and chemical properties of eumelanin. Pigment Cell Res 2006 ; 19 : 572-94.
 
5) Yamaguchi Y, Takahashi K, Zmudzka BZ, et al. Human skin responses to UV radiation : pigment in the upper epidermis protects against DNA damage in the lower epidermis and facilitates apoptosis. FASEB J 2006 ; 20 : 1486-8.
PubMed
P.27 掲載の参考文献
1) Takeuchi S, Zhang W, Wakamatsu K, et al. Melanin acts as a potent UVB photosensitizer to cause an atypical mode of cell death in murine skin. Proc Natl Acad Sci U S A 2004 ; 101 : 15076-81.
PubMed
2) Bush WD, Garguilo J, Zucca FA, et al. The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc Natl Acad Sci U S A 2006 ; 103 : 14785-9.
 
3) Mars U, Larsson BS. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res 1999 ; 12 : 266-74.
PubMed
4) Costin GE, Valencia JC, Wakamatsu K, et al. Mutations in dopachrome tautomerase (Dct) affect eumelanin/pheomelanin synthesis, but do not affect intracellular trafficking of the mutant protein. Biochem J 2005 ; 391 : 249-59.
 
5) Chintala S, Li W, Lamoreux ML, et al. Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. Proc Natl Acad Sci U S A 2005 ; 102 : 10964-9.
PubMed
6) Ito S, Nakanishi Y, Valenzuela RK, et al. Usefulness of alkaline hydrogen peroxide oxidation to analyze eumelanin and pheomelanin in various tissue samples : application to chemical analysis of human hair melanins. Pigment Cell Melanoma Res 2011 ; 24 : 605-13.
PubMed
7) Tadokoro T, Kobayashi N, Zmudzka BZ, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. FASEB J 2003 ; 17 : 1177-9.
PubMed
8) Peles DN, Simon JD. The ultraviolet absorption coefficient of melanosomes decreases with increasing pheomelanin content. J Phys Chem B 2010 ; 114 : 9677-83.
 
9) Maresca V, Flori E, Briganti S, et al. UVA-induced modification of catalase charge properties in the epidermis is correlated with the skin phototype. J Invest Dermatol 2006 ; 126 : 182-90.
PubMed
10) Hill HZ. The function of melanin or six blind people examine an elephant. Bioessays 1992 ; 14 : 49-56.
 
P.30 掲載の参考文献
1) 松永佳世子. シミの種類と治療法の選択. J Visual Dermatol 2004 ; 3 : 1058-64.
 
2) 橋本卓弥, 山下香緒里, 山崎和広, ほか. 顔角層細胞内メラニンの分析と定量的評価に関する研究. 日本機械学会論文集C編 2010 ; 78 : 160-76.
 
3) Ando H, Matsui MS, Ichihashi M. Quasi-drugs developed in Japan for the prevention or treatment for hyperpigmentary disorders. Int J Mol Sci 2010 ; 11 : 2566-75.
PubMed
4) 市橋正光. 高齢化社会を若々しく生きるためのアンチエイジング. 日臨皮医会誌 2007 ; 24 : 26-31.
 
5) Iriyama S, Ono T, Aoki H, et al. Hyperpigmentation in human solar lentigo is promoted by heparanase-induced loss of heparan sulfate chains at the dermal-epidermal junction. J Dermatol Sci 2011 ; 64 : 223-8.
PubMed
6) Aoki H, Moro O, Tagami H, et al. Gene expression profiling analysis of solar lentigo in relation to immunohistochemical characteristics. Br J Dermatol 2007 ; 156 : 1214-23.
PubMed
7) 渡辺晋一. 皮膚科におけるレーザー治療の基本原理. 日レ医誌 2006 ; 27 : 315-26.
 
8) 古川福実, 松永佳世子, 秋田浩孝, ほか. 日本皮膚科学会ケミカルピーリングガイドライン (改訂第3版). 日皮会誌 2008 ; 118 : 347-55.
 
9) Wang B. Photoaging : a review of current concepts of pathogenesis. J Cutan Med Surg 2011 ; 15 : S374-7.
PubMed
10) Kang HY, Valerio L, Bahadoran P, et al. The role of topical retinoids in the treatment of pigmentary disorders : an evidence-based review. Am J Clin Dermatol 2009 ; 10 : 251-60.
PubMed
11) Babizhayev MA, Deyev AI, Savel'yeva EL, et al. Skin beautification with oral non-hydrolized versions of carnosine and carcinine : effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging. J Dermatolog Treat 2011 Jul 14. [Epub ahead of print].
 
12) Scherbaum K, Ritschel T, Hullin1 M, et al. Computer-suggested facial makeup. Comput Graph Forum 2011 ; 30 : 485-92.
 
P.42 掲載の参考文献
1) 市橋正光. 高齢化社会を若々しく生きるためのアンチエイジング. 日臨皮医会誌 2007 ; 24 : 26-31.
 
2) 古江増隆, 山崎雙次, 神保孝一, ほか. 本邦における皮膚科受診患者の多施設横断四季別全国調査. 日皮会誌 2009 ; 119 : 1795-1809.
 
3) Ortiz A, Grando SA. Smoking and the skin. Int J Dermatol 2012 ; 51 : 250-62.
PubMed
4) 吉永信治, 保田浩志. 航空機乗務員のがんとその他の疾患 : 疫学研究による最近の知見. 放射線科学 2005 ; 48 : 52-61.
 
5) かづきれいこ, 百束比古. リハビリメイクが更年期症状に及ぼす効果 : WHOQOL26, VAS, クッパーマン更年期障害指数を用いた評価. 女性心身医学 2009 ; 14 : 85-93.
 
6) Lieu TJ, Pandya AG. Melasma quality of life measures. Dermatol Clin 2012 ; 30 : 269-80.
PubMed
7) Heckman CJ, Manne SL. Skin cancer and other health effects of indoor tanning (Chapter 6). In : Heckman CJ, et al, editors. Shedding Light on Indoor Tanning. New York/Heidelberg : Springer ; 2012. pp95-106.
 
8) 岡村理栄子. 子どもたちのおしゃれ障害. 香粧会誌 2011 ; 35 : 113-7.
 
P.50 掲載の参考文献
1) 吉村浩太郎. レチノイン酸を用いたfacial rejuvenation : 治療に必要な外用剤, スキンケア. 形成外科 1999 ; 42 : 801-6.
 
2) 芋川玄爾. スキンケア用品/美白剤. 田上八朗, 編. 皮膚科診療プラクティス 5. スキンケアの実際. 東京 : 文光堂, 1999. pp42-4.
 
3) 片桐崇行. 美白剤. 日本美容皮膚科学会, 監修. 美容皮膚科学. 東京 : 南山堂 ; 2005. pp291-4.
 
4) 船坂陽子. 美白剤の作用機序と効果. 日皮会誌 2010 ; 120 : 2828-31.
 
5) 関東裕美. 接触皮膚炎-美白剤による症例. 皮膚病診療 2005 ; 27 : 885-8.
 
P.55 掲載の参考文献
1) Pan MH, Lai CS, Tsai ML, et al. Molecular mechanisms for anti-aging by natural dietary compounds. Mol Nutr Food Res 2012 ; 56 : 88-115.
PubMed
2) Vanden Berghe W, Ndlovu MN, Hoya-Arias R, et al. Keeping up NF-kappaB appearance : epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 2006 ; 72 : 1114-31.
PubMed
3) Szarc vel Szic K, Ndlovu MN, Haegeman G, et al. Nature or nurture : let food be your epigenetic medicine in chronic inflammatory disorders. Biochem Pharmacol 2010 ; 80 : 1816-32.
PubMed
4) Ichihashi M, Ando H, Yoshida M, et al. Photoaging of the skin. Anti-Aging Med 2009 ; 6 : 46-59.
 
5) Maeda K, Fukuda M. Arbutin : mechanism of its depigmenting action in human melanocyte culture. J Pharm Exp Ther 1996 ; 276 : 765-9.
 
6) Shimogaki H, Tanaka Y, Tamai H, et al. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int J Cosmet Sci 2000 ; 22 : 291-303.
PubMed
7) Ando H, Watabe H, Valencia JC, et al. Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase : a new aspect of ubiquitin-proteasome function. J Biol Chem 2004 ; 279 : 15427-33.
PubMed
8) Imokawa G, Kobayashi T, Miyagishi M, et al. The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res 1997 ; 10 : 218-28.
PubMed
9) Ichihashi M, Kobayashi A, Okuda M, et al. Effect of chamomilla extracts application on UV-induced pigmentation. Skin Res (Hifu) 1999 ; 41 : 475-80. (in Japanese)
 
10) Maeda K, Hatao M. Involment of photooxidation of melanogenic precursors in prolonged pigmentation induced by ultraviolet A. J Invest Dermatol 2004 ; 122 : 503-9.
 
11) Tang X, Kim AL, Kopelvich L, et al. Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice. Photochem Photobiol 2008 ; 84 : 522-7.
 
12) Katiyar SK, Perez A, Mukhtar H. Green tea polyphenol treatment to human skin prevents formation of ultraviolet light B-induced pyrimidine dimmers in DNA. Clinical Cancer Res 2000 ; 6 : 3864-9.
 
13) Stahl W, Sies H. Carotenoids and flavonoids contribute to nutritional protection against skin damage from sunlight. Mol Biotechnol 2007 ; 37 : 26-30.
PubMed
14) 山下栄次. アスタキサンチン含有健康補助食品の美容効果. FOOD Style 21 2005 ; 9 : 72-5.
 
15) Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols : anti-inflammatry, antioxidant and DNA repair mechanisms. Arch Dermatol Res 2010 ; 302 : 71-83.
 
16) Wu Y, Jia LL, Zheng Y-N, et al. Resveratrate protects human skin from damage due to repetitive ultraviolet irradiation. J Eur Acad Dermatol Venereol 2012 online publication.
 
17) Renouf M, Guy P, Marmet C, et al. Plasma appearance and correlation between coffee and green tea metabolites in human subjects. Br J Nutr 2010 ; 104 : 1635-40.
PubMed
18) Heinrich U, Neukam K, Tronnier H, et al. Long-term ingestion of high flavanol cocoa provides photoprotection against UV-induced erythema and improve skin condition in women. J Nutr 2006 ; 136 : 1565-9.
PubMed
19) Ando H, Niki Y, Ito M, et al. Melanosomes are transferred from melanocytes to keratinocytes through the processes of packaging, release, uptake, and dispersion. J Invest Dermatol 2012 ; 132 : 1222-9.
PubMed
P.64 掲載の参考文献
1) 松永佳代子. しみと呼ばれる良性後天性色素沈着・増加症. 日本美容皮膚科学会, 監修. 美容皮膚科学. 改訂2版. 東京 : 南山堂 ; 2009. pp591-603.
 
2) Jang YH, Lee JY, Kang HY, et al. Oestrogen and progesterone receptor expression in melasma : an immunohistochemical analysis. J Eur Acad Dermatol Venereol 2010 ; 24 : 1312-6.
PubMed
3) 吉村浩太郎. トレチノイン療法. 日本美容皮膚科学会, 監修. 美容皮膚科学. 改訂2版. 東京 : 南山堂 ; 2009. pp289-98.
 
4) Kurita M, Kato H, Yoshimura K. A therapeutic strategy based on histological assessment of hyperpigmented skin lesions in Asians. J Plast Reconstr Aesthet Surg 2009 ; 62 : 955-63.
PubMed
P.76 掲載の参考文献
1) Sheth VM, Pandya AG. Melasma : a comprehensive update. Part I. J Am Acad Dermatol 2011 ; 65 : 689-97.
 
1) 船坂陽子. ケミカルピーリングの疾患別治療プログラム : しみ. 松永佳世子, ほか編. 皮膚科診療プラクティス 11. ケミカルピーリングとコラーゲン注入のすべて-美容皮膚科最前線. 東京 : 文光堂 ; 2001. pp112-21.
 
2) Sheth VM, Pandya AG. Melasma : a comprehensive update. Part II. J Am Acad Dermatol 2011 ; 65 : 699-714.
 
2) Lee DJ, Lee J, Ha J, et al. Defective barrier function in melasma skin. J Eur Acad Dermatol Venereol 2011 Nov 12. [Epub ahead of print].
 
3) Kang HY, Bahadoran P. Application of in vivo reflectance confocal microscopy in melasma classificaion. J Am Acad Dermatol 2012 ; 67 : 157.
 
P.81 掲載の参考文献
1) Bastiaens M, Huurne HT, Gruis N, et al. The melanocortin-1 receptor gene is the major freckle gene. Hum Mol Genet 2001 ; 10 : 1701-8.
 
1) Mosher DB, Fitzpatrick TB, Ortonne JP, et al. Hypomelanoses and Hypermelanoses. Freedberg IM, et al, editors. Fitzpatrick's Dermatology in General Medicine. 5th ed. Vol.1. New York : McGraw-Hill ; 1999. pp945-1017.
 
2) 鳥居秀嗣. シミの種類と診断. MB Derma 2006 ; 118 : 12-7.
 
2) Motokawa T, Kato T, Hashimoto Y, et al. Polymorphism patterns in the promoter region of the MC1R gene are associated with development of freckles and solar lentigines. J Invest Dermatol 2008 ; 128 : 1588-91.
PubMed
3) 河野通浩. 雀卵斑. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002, pp30-2.
 
4) Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995 ; 11 : 328-30.
PubMed
5) 稲垣克彦, 伊藤史朗, 鈴木教之, ほか. 色素異常症 (白斑・色素沈着). MB Derma 2004 ; 93 : 198-204.
 
6) 渡辺晋一. シミ・ソバカスの実態. 香粧会誌 2000 ; 24 : 287-95.
 
7) 渡辺晋一. 後天性色素沈着症の診断と治療. 日皮会誌 2009 ; 119 : 3023-8.
 
P.84 掲載の参考文献
1) 谷野博. 眼・上顎部褐青色母斑 (太田) [nevus fusco-caeruleus ophthalmpmaxillaris (Ota)] ニ就テ. 第一編. 症例報告及ビ部位, 配列, 色彩, 組織像ノ観察. 日皮会誌 1939 ; 46 : 435-51.
 
2) Hidano A, Kajima H, Ikeda S, et al. Natural history of nevus of Ota. Arch Dermatol 1967 ; 95 : 187-95.
PubMed
3) 井上勝平. 太田母斑の研究. 日皮会誌 1967 ; 77 : 291-325.
 
4) 肥田野信. 太田母斑. 久木田淳, ほか編. 現代皮膚科学大系 11. メラノサイト系腫瘍 母斑・母斑症. 東京 : 中山書店 ; 1982. pp191-200.
 
5) 肥田野信, 加島英雄. 両側性太田母斑. 皮膚臨床 1965 ; 7 : 72-81.
 
6) Watanabe S, Takahashi H. Treatment of nevus of Ota with Q-switched ruby laser. N Engl J Med 1994 ; 331 : 1745-50.
PubMed
P.87 掲載の参考文献
1) 肥田野信, 加島英雄. 両側性太田母斑. 皮膚臨床 1965 ; 7 : 72-81.
 
2) 金子佳世子. 顔面対称性後天性真皮メラノサイトーシス (仮称). 皮膚臨床 1988 ; 30 : 1649-59.
 
3) 村上富美子, 溝口昌子. 後天性対称性真皮メラノサイトーシスの100例の臨床的検討-特徴, 発祥機序および治療. Aesthet Dermatol 2004 ; 14 : 172-9.
 
4) 溝口昌子. 対称性真皮メラノサイトーシス. 日皮会誌 2006 ; 116 : 1993-7.
 
5) Hori Y, Kawashima M, Ohara K, et al. Aquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984 ; 10 : 961-4.
 
6) Sun CC, Lu YC, Lee EF, et al. Naevus fusco-caeruleus zygomaticus. Br J Dermatol 1987 ; 117 : 545-53.
PubMed
7) Murakami F, Soma Y, Mizoguchi M. Aquired symmetrical dermal melanocytosis (Naevus of Hori) developing after aggravated atopic dermatitis. Br J Dermatol 2005 ; 152 : 903-8.
 
8) 伊藤治夫, 中島静香, 原田裕之. 広範囲に発症し, 口蓋メラノーシスを伴ったAquired Dermal Melanocytosisの1例. 皮膚臨床 1996 ; 38 : 2081-5.
 
9) Murakami F, Baba T, Mizoguchi M. Ultraviolet-induced generalized aquired dermal melanocytosis with numerous melanophages. Br J Dermatol 2000 ; 142 : 184-6.
 
10) 神成摩耶, 村上富美子, 大岡志穂, ほか. 太田母斑を合併した後天性対称性真皮メラノサイトーシスの4例. 皮膚臨床 2006 ; 48 : 416-22.
 
11) 佐藤研士, 矢嶋明子, 吉田正己. 右手掌に生じた後天性真皮メラノサイトーシス. 皮膚臨床 2008 ; 50 : 81-3.
 
P.93 掲載の参考文献
1) 竹内かおり, 根岸圭, 櫛方晴, ほか. Q スイッチレーザー治療における炎症後色素沈着の発生率の検討. Aesthetic Dermatol 2008 ; 18 : 77-83.
 
2) Costin GE, Hearing VJ. Human skin pigmentation : melanocytes modulate skin color in response to stress. FASEB J 2007 ; 21 : 976-94.
PubMed
3) 芋川玄爾. ストレスと色素細胞-日焼け遺伝学を中心として. 生物の科学 遺伝 2009 ; 63 : 56-62.
 
4) 浅井純, 竹中秀也. 創傷治癒と局所因子. MB Derma 2007 ; 129 : 18-23.
 
5) Yamaguchi Y, Hearing VJ. Physiological factors that regulate skin pigmentation. Biofacotrs 2009 ; 35 : 193-9.
PubMed
6) Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997 ; 16 : 36-43.
PubMed
P.99 掲載の参考文献
1) Dubin DB, Barba AR, Sober AJ. Drug-induced or -related pigmentation. In : Nordlund JJ, et al, editors. The Pigmentary System : Physiology and Pathophysiology. New York : Oxford University Press ; 1998. pp915-35.
 
2) 塩原哲夫. 固定薬疹. 日皮会誌 2010 ; 120 : 1157-63.
 
3) 松本真明, 松本喜美, 池田光徳, ほか. 固定薬疹の色素沈着に関する肥満細胞の役割. 西日皮膚 2005 ; 67 : 490-4.
 
4) Seiberg M. Keratinocyte-melanocyte interactions during melanosome transfer. Pigment Cell Res 2001 ; 14 : 236-42.
PubMed
5) Gordon G, Sparano BM, Iatropoulos MJ. Hyperpigmentation of the skin associated with minocycline therapy. Arch Dermatol 1985 ; 119 : 618.
 
6) Okada N, Sato S, Sasou T, et al. Characterization of pigmented granules in minocycline-induced cutanous pigmentation : observations using fluorescence microscopy and high-performance liquid chromatography. Br J Dermatol 1993 ; 129 : 403-7.
PubMed
7) 大森香央, 林伸和, 川島眞. 下腿に生じたミノサイクリンによる色素沈着. 臨皮 2010 ; 64 : 831-4.
 
8) Sato E, Tsukimoto M, Shimura N, et al. Mechanism of pigmentation by minocycline in murine B16 melanoma cell. Yakugaku Zasshi 2011 ; 131 : 731-8.
PubMed
9) 宇原久, 古賀弘志, 河内繁雄, ほか. 色素病変-抗癌剤による症例. 皮膚病診療 2007 ; 29 : 43-6.
 
10) 佐藤和子, 深谷徹, 大河原章. フトラフールによる薬疹の4例. 皮膚臨床 1992 ; 34 : 583-8.
 
11) 渡辺玲, 池田美智子, 南光弘子, ほか. 兎眼, 視力低下を併発したテガフール配合剤による薬疹の1例. 皮膚臨床 2004 ; 46 : 463-7.
 
12) 小木曽政則, 伊藤正夫, 沢木佳弘, ほか. PeplomycinによるScratch dermatitisの3症例. 口科誌 1991 ; 40 : 893-9.
 
13) 田中美佐子, 田上八朗. ペプロマイシン注射によるscratch dermatitis型薬疹. 臨皮 1998 ; 52 : 510-2.
 
P.106 掲載の参考文献
1) 谷垣武彦, 畑清一郎, 喜多野征夫, ほか. 躯幹, 四肢に発生した特異な色素沈着症 "ナイロン製布摩擦皮膚症" (Nylon clothes friction dermatosis) の疫学 : 第2報. 日皮会誌 1985 ; 95 : 1159-64.
 
2) 姉小路公人, 中澤朗子. 摩擦黒皮症. 皮膚臨床 1992 ; 34 : 1209-15.
 
3) 松本京子, 宮崎千春, 三次経子, ほか. 横浜労災病院に於ける摩擦黒皮症の疫学調査. 日本災害医学会雑誌 1999 ; 47 : 199-205.
 
4) 小野紀子, 陳科栄. 男性様顔貌を呈した摩擦黒皮症の1例. 臨皮 2005 ; 59 : 600-2.
 
5) Kurita M, Okazaki M, Fujino T, et al. Cyclic stretch induces upregulation of endothelin-1 with keratinocytes in vitro : possible role in mechanical stress-induced hyperpigmentation. Biochem Biophys Res Commun 2011 ; 409 : 103-7.
PubMed
6) Chuang YY, Lee DD, Lin CS, et al. Characteristic dermoscopic features of primary cutaneous amyloidosis : a study of 35 cases. Br J Dermatol 2012 May 25. [Epub ahead of print].
 
7) 武藤公一郎, 中村昭典. 若年女性の躯幹にみられた色素沈着. 日皮会誌 1980 ; 90 : 741.
 
P.111 掲載の参考文献
1) 末木博彦. 糖尿病3 大合併症と前脛骨部色素斑. MB Derma 2004 ; 85 : 30-34.
 
2) Sadeghian G, Ziaie H, Amini M, et al. Evaluation of insulin resistance in obese women with and without acanthosis nigricans. J Dermatol 2009 ; 4 : 209-12.
PubMed
3) 大塚俊, 田辺昭子, 山陰明生, ほか. インスリン受容体異常症に伴った良性黒色表皮腫の1例. 臨皮 2000 ; 54 : 1079-82.
 
4) 岡山悟志, 和田洵子, 吉本宗平, ほか. 高齢発症の緩徐進行型1型糖尿病に慢性甲状腺炎, 萎縮性胃炎, 尋常性白斑を合併した多腺性自己免疫症候群III型の1例. 糖尿病 2005 ; 48 : 491-5.
 
5) 金澤寧彦, 暢原寿一, 大久保佳昭, ほか. 1型糖尿病, 特発性甲状腺機能低下症に橋本病, 尋常性白斑を併発した多腺性自己免疫症候群の1例. 糖尿病 2006 ; 49 : 445-9.
 
6) 矢崎正英, 鈴木彩子, 池田修一, ほか. アミロイド沈着の生化学的分析-微小生検組織を用いたアミロイド蛋白の解析. 生物物理化学 2010 ; 54 : 19-22.
Medical*Online
7) 松尾宏美, 神谷受利, 味岡正純. 皮膚生検が診断の契機となった全身性アミロイドーシスの1例. 皮膚臨床 2011 ; 53 : 664-5.
 
P.118 掲載の参考文献
1) Kemkemer R, Schrank S, Vogel W, et al. Increased noise as an effect of haploinsufficiency of the tumor-suppressor gene neurofibromatosis type 1 in vitro. Proc Natl Acad Sci USA 2002 ; 99 : 13783-8.
PubMed
1) Reichrath J. Vitamin D and the skin : an ancient friend, revisited. Exp Dermatol 2007 : 16 : 618-25.
PubMed
2) Imokawa G. Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigm Cell Res 2004 ; 17 : 96-110.
 
3) Nakayama J, Kiryu H, Urabe K, et al. Vitamin D3 analogues improve cafe au lait spots in patients with von Recklinghausen's disease : experimental and clinical studies. Eur J Dermatol 1999 ; 9 : 202-6.
PubMed
4) 古村南夫, 中山樹一郎. 神経線維腫症1型の病態と治療 (II) -カフェ・オ・レ斑の発症病理. 西日皮膚 2010 ; 72 : 500-6.
 
5) 佐藤典子, 中園亜矢子, 古村南夫, ほか. レックリングハウゼン病の色素斑に対するフォトRF照射及び活性型ビタミンD3誘導体軟膏外用治療の効果. 日皮会誌 2005 ; 115 : 579-84.
 
P.123 掲載の参考文献
1) Peutz JLA. Very remarkable case or familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentation of the skin and mucous membrane. Nederl Maandschr v Geneesk 1921 ; 10 : 134-46.
 
2) Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits : a syndrome of diagnostic significance. N Engl J Med 1949 ; 241 : 993-1005.
PubMed
3) Bruwer A, Bargen JA, Kierland RR. Surface pigmentation and generalized intestinal polyposis ; (Peutz-Jeghers syndrome). Proc Staff Meet Mayo Clin 1954 ; 29 : 168-71.
PubMed
4) 長洲光太郎, 阿部元嵐. 異常色素沈着症を伴った全腸管ポリポーシスの1例. 臨消病学 1955 ; 3 : 156-8.
 
5) Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome : a systematic review and recommendations for management. Gut 2010 ; 59 : 975-86.
PubMed
6) Amos CI, Keitheri-Cheteri MB, Sabripour M, et al. Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet 2004 ; 41 : 327-33.
PubMed
7) Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006 ; 4 : 408-15.
PubMed
8) Soyer P, Argenziano A, Ruocco V, et al. Dermoscopy of pigmented skin lesions. Eur J Dermatol 2001 ; 11 : 270-6.
 
9) Soyer P, Argenziano A, Ruocco V, et al. Dermoscopy of pigmented skin lesions (Part II). Eur J Dermatol 2001 ; 11 : 483-98.
 
10) 早川和人, 武林亮子. Case31 Peutz-Jeghers症候群 vs アトピー性口唇メラノーシス vs Laugier-Hunziker-Baran症候群. 塩原哲夫, 監修. 皮膚科の似たもの同士 : 目で見る鑑別診断. 東京 : 学研メディカル秀潤社 ; 2010. pp150-5.
 
11) 上出良一, 石川優子, 伊部美葉, ほか. アトピー性口唇メラノーシス. 皮膚病診療 1996 ; 18 : 351-4.
 
12) 山上淳, 藤本篤嗣, 小菅治彦, ほか. 若年発症したLaugier病の1例. 皮膚臨床 2003 ; 45 : 473-5.
 
13) Carli P, DeGiorgi V, Cattaneo A, et al. Mucosal melanosis clinically mimicking malignant melanoma : non invasive analysis by epiluminescence microscopy. Eur J Dermatol 1996 ; 6 : 434-6.
 
14) Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006 ; 12 : 3209-15.
PubMed
15) Xi Z, Hui Q, Zhong L. Q-switched alexandrite laser treatment of oral labial lentigines in Chinese subjects with Peutz-Jeghers syndrome. Dermatol Surg 2009 ; 35 : 1084-8.
 
16) Klumpen HJ, Queiroz KC, Spek CA, et al. mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome. J Clin Oncol 2011 ; 29 : e150-3.
 
P.129 掲載の参考文献
1) 遠山郁三. 一種ノ色素沈着症. 皮膚科及泌尿器科雑誌 1910 ; 10 : 644.
 
2) Suzuki N, Suzuki T, Inagaki K, et al. Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularis. J Invest Dermatol 2005 ; 124 : 1186-92.
PubMed
3) Miyamura Y, Suzuki T, Kono M, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet 2003 ; 73 : 693-9.
PubMed
4) Oyama M, Shimizu H, Ohata Y, et al. Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi) : report of a Japanese family with the condition and a literature review of 185 cases. Br J Dermatol 1999 ; 140 : 491-6.
 
5) 鈴木民夫. 遺伝子変異による色素異常症. MB Derma 2010 ; 163 : 47-54.
 
6) Wang Q, Miyakoda M, Yang W, et al. Stress induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004 ; 279 : 4952-61.
 
7) 林昌浩, 鈴木民夫. 遺伝性色素異常症の遺伝子診断. 皮膚病診療 2010 ; 32 (増刊) : 32-8.
 
8) Patrizi A, Manneschi V, Pini A, et al. Dyschromatosis symmetrica hreditaria associated with idiopathic torsion dystonia. A case report. Acta Derm Venereol 1994 ; 74 : 135-7.
PubMed
9) 小林浩, 奥村秀弘. 遺伝性対側性色素異常症の1例. 臨床皮膚泌尿器科 1962 ; 16 : 1045-7.
 
10) Tan HH, Tay YK. Neurofibromatosis and reticulate acropigmentation of Dohi : a case report. Pediatr Dermatol 1997 ; 14 : 296-8.
PubMed
11) 矢澤徳仁, 湧川基史, 藤本学, ほか. 特異な臨床像を呈した遺伝性対側性色素異常症と全身性強皮症の合併例. 皮膚臨床 1997 ; 39 : 107-11.
 
12) 鈴木民夫. 遺伝性色素異常症. 日皮会誌 2008 ; 118 : 2614-6.
 
P.132 掲載の参考文献
1) Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008 ; 3 : 13.
PubMed
2) Gorlin RJ, Anderson RC, Blaw M. Multiple lentigines syndrome. Am J Dis Child 1969 ; 17 : 652-62.
 
3) Tartaglia M, Martinelli S, Stella L, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006 ; 78 : 279-90.
PubMed
4) Zenker M. Genetic and pathogenetic aspects of Noonan syndrome and related disorders. Horm Res 2009 ; 72 (Suppl 2) : 57-63.
 
5) Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006 ; 12 : 283-5.
PubMed
6) Digilio MC, Sarkozy A, Pacileo G, et al. PTPN11 gene mutations : linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype". Eur J Pediatr 2006 ; 165 : 803-5.
 
7) Digilio MC, Sarkozy A, de Zorzi A, et al. LEOPARD syndrome : clinical diagnosis in the first year of life. Am J Med Genet A 2006 ; 140 : 740-6.
PubMed
P.137 掲載の参考文献
1) Komune N, Hara T, Tamae A, et al. A case of laryngeal carcinoma in a young adult with dyskeratosis congenital. Int J Clin Oncol 2010 ; 15 : 428-32.
 
2) Dokal I, Vulliamy T, Mason P, et al. Clinical utility gene card for : dyskeratosis congenita. Eur J Hum Genet 2011 Nov ; 19 (11). doi : 10.1038/ejhg.2011.90. Epub 2011 May 25.
 
3) Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenital. Br J Haematol 2009 ; 145 : 164-72.
PubMed
4) Walne AJ, Vulliamy T, Beswick R, et al. Mutations in C16orf57 and normal-length telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndrome. Hum Mol Genet 2010 ; 19 : 4453-61.
 
5) Abreu E, Aritonovska E, Reichenbach P, et al. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol Cell Biol 2010 ; 30 : 2971-82.
PubMed
P.141 掲載の参考文献
1) 澤村大輔, 池田志斈, 鈴木民夫, ほか. 日本皮膚科学会ガイドライン 皮膚疾患遺伝子診断ガイドライン (第1版). 日皮会誌 2012 ; 122 : 561-73.
 
P.148 掲載の参考文献
1) Jux B, Kadow S, Luecke S, et al. The aryl hydrocarbon receptor mediates UVB radiation-induced skin tanning. J Invest Dermatol 2011 ; 131 : 203-10.
PubMed
2) Maeda K, Hatao M. Involvement of photooxidation of melanogenic precursors in prolonged pigmentation induced by ultraviolet A. J Invest Dermatol 2004 ; 122 : 503-9.
 
P.152 掲載の参考文献
1) 杉山清治. 新美白剤の評価-ルシノールについて. 皮膚と美容 1998 ; 30 : 5168-72.
 
2) 片桐崇行, 大久保禎, 及川みどり, ほか. 4-n-ブチルレゾルシノール (ルシノール(R)) のメラニン産生抑制作用とヒト色素沈着に対する有効性. J Soc Cosmet Chem Japan 2001 ; 35 : 42-9.
 
3) ルシノール(R) 研究会. 肝斑に対するルシノール(R) (4-n-butylresorcinol) の有用性に関する研究. 西日皮膚 1999 ; 61 : 813-9.
 
4) リノール酸配合外用剤臨床研究班. リノール酸配合外用剤の肝斑に対する臨床効果. 西日皮膚 1998 ; 60 : 537-42.
 
5) 前田憲寿. B 紫外線による色素沈着メカニズムと色素沈着に対するt-AMCHA外用の効果. Fragrance Journal 2003 ; 31 (臨時増刊) : 42-9.
 
6) 喜多陽子, 須貝哲郎. 肝斑に対する美白剤の効果. 皮膚 1992 ; 34 : 142-6.
 
7) Motokawa T, Kato T, Hashimoto Y, et al. Effect of Val92Met and Arg163Gln variants of the MC1R gene on freckles and solar lentigines in Japanese. Pigment Cell Res 2007 ; 20 : 140-3.
PubMed
8) 吉野昇, 五十嵐幸代. 細胞内ATP濃度調節に着目した新しい美白製品の開発. ファルマシア 2008 ; 44 : 412-6.
 
9) Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002 ; 147 : 20-31.
PubMed
10) 箱崎智洋. 最近の美白研究を探る : ニコチン酸アミドの美白効果とそのメカニズム. Fragrance Journal 2005 ; 33 : 55-9.
 
11) Akasaka T, Ohurazaka H, Nishioheda G, et al. Topically applied 0.3 % 4-n-butylresorcinol decreases pigmentation after laser therapy. Environ Dermatol 2002 ; 9 : 11-5.
 
P.158 掲載の参考文献
1) Warren JB. Nitric oxide and human skin blood flow responses to acetylcholine and ultraviolet light. FASEB J 1994 ; 8 : 247-51.
PubMed
2) Rhodes LE, Gledhill K, Masoodi M, et al. The sunburn response in human skin is characterized by sequential eicosanoid profiles that may mediate its early and late phases. FASEB J 2009 ; 23 : 3947-56.
PubMed
3) Schallreuter KU, Chavan B, Rokos H, et al. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab 2005 ; 86 (Suppl 1) : S27-33.
 
4) Schallreuter KU, Wazir U, Kothari S, et al. Human phenylalanine hydroxylase is activated by H2O2 : a novel mechanism for increasing the L-tyrosine supply for melanogenesis in melanocytes. Biochem Biophys Res Commun 2004 ; 322 : 88-92.
 
5) Sasaki M, Kizawa K, Igarashi S, et al. Suppression of melanogenesis by induction of endogenous intracellular metallothionein in human melanocytes. Exp Dermatol 2004 ; 13 : 465-71.
PubMed
6) Ochiai Y, Kaburagi S, Okano Y, et al. A Zn (II) -glycine complex suppresses UVBinduced melanin production by stimulating metallothionein expression. Int J Cosmet Sci 2008 ; 30 : 105-12.
PubMed
7) Sasaki M, Horikoshi T, Uchiwa H, et al. Up-regulation of tyrosinase gene by nitric oxide in human melanocytes. Pigment Cell Res 2000 ; 13 : 248-52.
PubMed
8) Yoshida E, Watanabe T, Takata J, et al. Topical application of a novel, hydrophilic gamma-tocopherol derivative reduces photo-inflammation in mice skin. J Invest Dermatol 2006 ; 126 : 1447-9.
 
9) Masaki H, Okano Y, Ochiai Y, et al. alpha-Tocopherol increases the intracellular glutathione level in HaCaT keratinocytes. Free Radic Res 2002 ; 36 : 705-9.
PubMed
10) Ochiai Y, Kaburagi S, Obayashi K, et al. A new lipophilic pro-vitamin C, tetra-isopalmitoyl ascorbic acid (VC-IP), prevents UV-induced skin pigmentation through its anti-oxidative properties. J Dermatol Sci 2006 ; 44 : 37-44.
PubMed
P.162 掲載の参考文献
1) 山下理絵. 肝斑の治療方法 : わたしはこうしている. 日本美容皮膚科学会雑誌 2010 ; 20 : 357-67.
 
1) 山下理絵. 美容医学でのアンチエイジング治療. 東京 : 文光堂 ; 2008.
 
2) 山下理絵. 皮膚レーザー治療のコツ : しみ. PEPARS 2006 ; No.7 : 50-7.
 
3) 山下理絵. 光老化に対するレーザー・光治療-シミ・しわの治療. 臨床スポーツ医学 2005 ; 22 : 47-52.
Medical*Online
4) 山下理絵. 肝斑の治療方法 : わたしはこうしている. 日本美容皮膚科学会雑誌 2010 ; 20 : 357-67.
 
5) 山下理絵. レーザー治療後の炎症性色素沈着に対するスキンケア : 老人性色素斑に対するレーザー治療と術前術後のスキンケア. 日本美容外科学会会報 1998 ; 20 : 1-7.
 
6) Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994 ; 20 : 592-7.
PubMed
7) Kawada A, Asai M, Kameyama H, et al. Videomicroscopic and histopathologicalo investigation of intense pulsed light therapy or solar lentigines. J Dermatol Science 2002 ; 29 : 91-6.
PubMed
8) 山下理絵. IPLによるしみ治療. PEPARS 2009 ; No.27 : 23-32.
 

II 白斑

P.172 掲載の参考文献
1) 鈴木民夫, 金田眞理, 種村篤, ほか. 尋常性白斑診療ガイドライン. 日皮会誌 2012 ; 122 : 1725-40.
 
2) Radtke MA, Schafer I, Gajur A, et al. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009 ; 161 : 134-9.
PubMed
3) 三嶋豊. 尋常性白斑. 東京 : 篠原出版 ; 1982.
 
4) Taieb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009 ; 360 : 160-9.
PubMed
5) 古江増隆, 山崎雙次, 神保孝一, ほか. 本邦における皮膚科受診患者の多施設横断四季別全国調査. 日皮会誌 2009 ; 119 : 1795-1809.
 
P.176 掲載の参考文献
1) Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993 ; 129 : 994-8.
PubMed
2) Lerner AB. On the etiology of vitiligo and grey hair. Am J Med 1971 ; 51 : 141-7.
PubMed
3) Howitz J, Brodthagen H, Schwartz M, et al. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977 ; 113 : 47-52.
PubMed
4) Venneker GT, de Waal LP, Westerhof W, et al. HLA associations in vitiligo patients in the Dutch population. Dis Markers 1993 ; 11 : 187-90.
PubMed
5) Yamaguchi Y, Hearing VJ. Physiological factors that regulate skin pigmentation. Biofactors 2009 ; 35 : 193-9.
PubMed
6) Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007 ; 356 : 1216-25.
PubMed
7) Cui J, Harning R, Henn M, et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992 ; 98 : 162-5.
PubMed
8) Norris DA, Horikawa T, Morelli JG. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994 ; 7 : 193-203.
PubMed
9) Lang KS, Caroli CC, Muhm A, et al. HLA-A2 restricted, melanocyte-specific CD8 (+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 2001 ; 116 : 891-7.
PubMed
10) Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydropterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochem Biophys Acta 1994 ; 1226 : 181-92.
PubMed
11) Passi S, Granditti M, Maggio F, et al. Epidermal oxidative stress in vitiligo. Pigment Cell Res 1998 ; 11 : 81-5.
 
12) Abadie MS, Senior HJ, Bleehen SS, et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994 ; 131 : 160-5.
 
13) Lazarova R, Hristakieva T, Lazarov N, et al. Vitiligo-related neuropeptides in nerve fibers of the skin. Arch Physiol Biochem 2000 ; 108 : 262-7.
 
14) 冨田靖, 鈴木民夫. メラニンと色素異常症. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp1-11.
 
15) 種村篤, 高橋彩, 上木裕理子, ほか. 尋常性白斑に対する活性型ビタミンD3外用と紫外線照射併用療法の有効性についての検討. 皮膚の科学 2011 ; 10 : 485-93.
 
P.181 掲載の参考文献
1) 片山一朗. 白斑・白皮症の全国調査 : 本邦での患者数と治療の実態に関する経過報告. 皮膚病診療 2010 ; 32 : 1022-9.
 
2) 鈴木民夫, 金田眞理, 種村篤, ほか. 尋常性白斑診療ガイドライン. 日皮会誌 2012 ; 122 : 1725-40.
 
3) 鈴木民夫. 症候群附随型眼皮膚白皮症 (syndromic oculocutaneous albinism). 皮膚病診療 2009 ; 31 : 289-95.
 
4) 占部和敬. 色素脱失のすべて : まだら症, Waardenburg症候群の診断と治療. MB Derma 2008 ; 143 : 33-40.
 
5) 河野通浩. 脱色素性母斑. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp160-3.
 
6) Miyamura Y, Suzuki T, Kono M, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet 2003 ; 73 : 693-9.
PubMed
7) 金田眞理. 結節性硬化症 from tuber to mTOR. 日皮会誌 2005 ; 115 : 848-56.
 
8) 端本宇志, 盛山吉弘. 皮膚外症状を欠くhypomelanosis of Ito. 皮膚病診療 2010 ; 32 : 951-4.
 
9) Tachibana M. A cascade of genes related to Waardenburg syndrome. J Investig Dermatol Symp Proc 1999 ; 4 : 126-9.
PubMed
10) 塚本克彦. 日常診療に役立つ皮膚科最新情報 : 白斑. 皮膚臨床 2009 ; 51 : 1503-9.
 
11) 古賀道之. 尋常性白斑. 皮膚臨床 2001 ; 43 : 39-45.
 
12) 山口裕史. Vogt-小柳-原田病における白斑の診断と治療. MB Derma 2008 ; 143 : 21-5.
 
13) 松本義也. 感染症に伴う白斑. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp280-4.
 
14) 塚本克彦. 白色粃糠疹. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp201-2.
 
P.191 掲載の参考文献
1) Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet 2009 ; 18 (R1) : R9-17.
PubMed
2) Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009 ; 41 : 920-5.
PubMed
3) Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010 ; 362 : 1686-97.
PubMed
4) Oiso N, Suzuki T, Fukai K, et al. Non-segmental vitiligo and autoimmune mechanism. Dermatol Res Pract 2011 ; 2011 : 518090.
PubMed
5) Lewis FM, Shah M, Messenger AG, et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992 ; 26 : 173-7.
 
6) Kunisada M, Kumimoto H, Ishizaki K, et al. Narrow-band UVB induces more carcinogenic skin tumors than broad-band UVB through the formation of cyclobutane pyrimidine dimer. J Invest Dermatol 2007 ; 127 : 2865-71.
PubMed
7) Motokawa T, Kato T, Hashimoto Y, et al. Effect of Val92Met and Arg163Gln variants of the MC1R gene on freckles and solar lentigines in Japanese. Pigment Cell Res 2007 ; 20 : 140-3.
PubMed
8) Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010 ; 362 : 1686-97.
PubMed
9) Narita T, Oiso N, Fukai K, et al. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int 2011 ; 60 ; 505-8.
PubMed
10) Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011 ; 6 : e18907.
 
11) Hexsel CL, Eide MJ, Johnson CC, et al. Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. J Am Acad Dermatol 2009 ; 60 : 929-33.
 
12) Nordlund JJ. Nonmelanoma skin cancer in vitiligo patients. J Am Acad Dermatol 2009 ; 61 : 1080-1.
PubMed
P.197 掲載の参考文献
1) Nagamine K, Peterson P, Scott H, et al. Positional cloning of the APECED gene. Nature Genet 1997 ; 17 : 393-8.
PubMed
2) Betterle C, Greggio NA, Volpato M. Autoimmune polyglandular syndrome type 1. Clin Endocr Metab 1998 ; 83 : 1049-55.
 
3) Collins SM, Domingues M, Ilmarinen T, et al. Dermatological manifestations of autoimmune polyendocirnopahy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 2006 ; 154 : 1088-93.
 
4) Cunliffe WJ, Hall R, Newell DJ, et al. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968 ; 80 : 135-9.
PubMed
5) Schallreuter KU, Lemke R, Brandt O, et al. Vitiligo and other diseases-coexistence or true association? Hambrug study on 321 patients. Dermatology 1994 ; 188 : 269-75.
PubMed
6) Birlea SA, Jin Y, Bennett DC, et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol 2011 ; 131 : 371-81.
PubMed
7) Ban Y, Tozaki T, Tobe T, et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity : an association analysis in Caucasian and Japanese cohorts. J Autoimmun 2007 ; 28 : 201-7.
PubMed
8) van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007 ; 2007 : 89017.
PubMed
9) Gould IM, Gray RS, Urbaniak SJ, et al. Vitiligo in diabetes mellitus. Br J Dermatol 1985 ; 113 : 153-5.
PubMed
10) Oiso N, Suzuki T, Fukai K, et al. Nonsegmental vitiligo and autoimmune mechanism. Dermatol Res Pract 2011 ; 2011 : 518090.
PubMed
11) Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011 ; 6 : e18907.
 
P.201 掲載の参考文献
1) 鈴木民夫, 金田眞理, 種村篤, ほか. 尋常性白斑診療ガイドライン. 日皮会誌 2012 ; 122 : 1725-40.
 
2) Jin Y, Mailloux CM, Gowan K, et al. NLRP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007 ; 356 : 1216-25.
PubMed
3) Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci 1991 ; 88 : 8696-99.
PubMed
4) 占部和敬. まだら症. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp151-4.
 
5) Lesser E. In : Ziemssen HV, et al, editors. Handbuch der Haukrankheiten. 1883. p183.
 
6) Coupe RL. Unilateral systematized achromic nevus. Dermatologica 1967 ; 134 : 19-35.
 
7) Monma F, Hozumi Y, Kawaguchi M, et al. A novel MITF splice site mutation in a family with Waardenburg syndrome. J Dermatol Sci 2008 ; 52 : 64-6.
 
8) Waardenburg PJ. A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet 1951 ; 3 : 195-253.
PubMed
9) Tomita Y, Suzuki T. Genetics of pigmentary disorders. Am J Med Genet 2004 ; 131C : 75-81.
PubMed
10) 伊藤実. 対側性列序性脱色素母斑の特異例. 日皮会誌 1951 ; 61 : 31.
 
11) 占部和敬. 白皮症・脱色素性母斑・伊藤白斑・結節性硬化症. MB Derma 2010 ; 164 : 168-72.
 
12) 橋本宇志, 盛山吉弘. 皮膚外症状を欠くhypomelanosis of Ito. 皮膚病診療 2010 ; 32 : 951-4.
 
13) 大塚藤男. 神経皮膚症候群-NF1, NF2と結節性硬化症. 西日皮膚 2002 ; 64 : 407-11.
 
14) Hyman MH, Whittemore VH. National Institutes of Health consensus conference : tuberous sclerosis complex. Arch Neurol 2000 ; 57 : 662-5.
PubMed
15) 林昌浩, 鈴木民夫. 遺伝性色素異常症の遺伝子診断. 皮膚病診療 2010 ; 32 (増刊) : 32-8.
 
P.206 掲載の参考文献
1) 鈴木民夫, 金田眞理, 種村篤, ほか. 尋常性白斑診療ガイドライン. 日皮会誌 2012 ; 122 : 1725-40.
 
2) 塚本克彦. 色素異常症 : 白斑. 皮膚臨床 2009 ; 51 (臨時増刊) : 1503-9.
 
3) Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo : a comprehensive overview. Part II : treatment options and approach to treatment. J Am Acad Dermatol 2011 ; 65 : 493-514.
PubMed
4) Taieb A, Picardo M. VETF Members. The definition and assessment of vitiligo : a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007 ; 20 : 27-35.
PubMed
5) Mahmoud BH, Hexsel CL, Hamzavi IH. An update on new and emerging options for the treatment of vitiligo. Skin Therapy Lett 2008 ; 13 : 1-6.
PubMed
6) Njoo MD, Westerhof W, Bos JD, et al. The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell' Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol 1999 ; 135 : 1514-21.
 
P.211 掲載の参考文献
1) 片山一郎. 白斑・白皮症の全国調査. 皮膚病診療 2010 ; 32 : 1022-9.
 
2) Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids : children with head and neck involvement respond well. J Am Acad Dermatol 2002 ; 46 : 964-5.
 
3) Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998 ; 134 : 1532-40.
PubMed
4) Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999 ; 135 : 1061-6.
 
5) Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo : therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004 ; 51 : 52-61.
PubMed
6) Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1 % tacrolimus vs 0.05 % clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 ; 139 : 581-5.
 
7) Radakovic S, Breier-Maly J, Konschitzky R, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus : a controlled prospective, randomized, observerblinded trial. Eur Acad Dermatol Venereol 2009 ; 23 : 951-3.
PubMed
8) Hartmann A, Brocker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1 % ointment in adult patients with vitiligo : results of a placebo-controlled 12-month prospective study. Acta Derm Venereol 2008 ; 88 : 474-9.
 
9) Fai D, Cassano N, Vena GA. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo : a review of 110 patients. J Eur Acad Dermatol Venereol 2007 ; 21 : 916-20.
PubMed
10) Ostovari N, Passeron T, Lacour JP, et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006 ; 142 : 252-3.
PubMed
11) Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser : a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004 ; 140 : 1065-9.
PubMed
12) Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006 ; 20 : 269-73.
PubMed
13) 大仁田亜紀, 芦田三輪. 尋常性白斑の外用療法. MB Derma 2008 ; 143 : 15-9.
 
14) Ermis O, Alpsoy E, Cetin L, et al. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001 ; 145 : 472-5.
PubMed
15) Katayama I, Ashida M, Maeda A, et al. Open trial of topical tacalcitol [1 alpha 24 (OH)2D3] and solar irradiation for vitiligo vulgaris : upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 2003 ; 13 : 372-6.
PubMed
P.214 掲載の参考文献
1) Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011 ; 6 : e18907.
 
2) Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999 ; 38 : 546-50.
PubMed
3) Seiter S, Ugurel S, Tilgen W, et al. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 2000 ; 39 : 624-7.
PubMed
4) Rath N, Kar HK, Sabhnani S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 2008 ; 74 : 357-60.
PubMed
5) Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 2006 ; 17 : 151-3.
PubMed
6) Dogra S, Kumar B. Repigmentation in vitiligo universalis : role of melanocyte density, disease duration, and melanocytic reservoir. Dermatol Online J 2005 ; 11 : 30.
 
7) Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990 ; 126 : 339-50.
PubMed
P.216 掲載の参考文献
1) 堀川達弥. 白斑の外科的治療の有効性について. MB Derma 2003 ; 81 : 170-4.
 
2) 堀川達弥. 白斑の外科療法. MB Derma 2008 ; 143 : 9-14.
 
3) 荒木敬司, 西野圭輔, 堀川達弥, ほか. 尋常性白斑への吸引表皮移植術. 皮膚 1991 ; 33 : 435-40.
 
4) Koga M. Epidermal grafting using the tops of suction blisters in the treatment of vitiligo. Arch Dermatol 1988 ; 124 : 1656-8.
PubMed
5) 加藤裕史, 新谷洋一, 渡辺正一, ほか. 尋常性白斑に対する1ミリミニグラフト療法の検討. 日皮会誌 2008 ; 118 : 2211-7.
 
6) McGovern TW, Bolognia J, Leffell D. Fip-top pigment transplantation. Arch Dermatol 1999 ; 135 : 1305-7.
 
7) 古賀道之. 尋常性白斑 : 外科療法. 皮膚臨床 1991 ; 33 : 1109-12.
 
P.220 掲載の参考文献
1) Xu AE, Huang B, Li YW, et al. Clinical, histopathological and ultrastructural characteristics of naevus depigmentosus. Clin Exp Dermatol 2008 ; 33 : 400-5.
 
2) Oiso N, Kawada A. The diagnostic usefulness of dermoscopy for nevus depigmentosus. Eur J Dermatol 2011 ; 21 : 639-40.
PubMed
3) Narita T, Oiso N, Fukai K, et al. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int 2011 ; 60 : 505-8.
PubMed
4) Murakami T, Fukai K, Oiso N, et al. New KIT mutations in patients with piebaldism. J Dermatol Sci 2004 ; 35 : 29-33.
PubMed
5) 大磯直毅, 川田暁. 脱色素性母斑 : 最近の知見. 日小皮会誌 2010 ; 29 : 85-9.
 
6) Oiso N, Kawara S, Kawada A. Acquired melanocytic naevus in naevus depigmentosus. Clin Exp Dermatol 2009 ; 34 : e311-2.
PubMed
7) Oiso N, Kawada A. Melanocytic nevi in nevus depigmentosus in a region of the body exposed to sunlight. J Eur Acad Dermatol Venereol 2011 ; 25 : 491-2.
 
8) Oiso N, Amatsu A, Kawada A. Hyperpigmented spots within and partly around a hypopigmented macule. Int J Dermatol 2011 ; 50 : 795-7.
PubMed
9) Oiso N, Kishida K, Fukai K, et al. A Japanese piebald patient with auburn hair color associated with a novel mutation p.P832L in the KIT gene and a homozygous variant p.I120T in the MC1R gene. Brit J Dermatol 2009 ; 161 : 468-9.
 
10) Narita T, Oiso N, Fukai K, et al. Two children with a mild or moderate piebaldism phenotype and a father without leukoderma in a family with the same recurrent missense mutation in the kinase domain of KIT. Eur J Dermatol 2011 ; 21 : 446-7.
PubMed
11) 大磯直毅. Hermansky-Pudlak syndromeの最新の知見 1. Hermansky-Pudlak syndromeの遺伝子群-ヒトと動物モデルの比較による新たな展開. 西日皮膚 2006 ; 68 : 3-10.
 
12) Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008 ; 159 : 1051-76.
PubMed
13) Katayama I, Ashida M, Maeda A, et al. Open trial of topical tacalcitol [1 alpha 24 (OH)2D3] and solar irradiation for vitiligo vulgaris : upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 2003 ; 13 : 372-6.
PubMed
14) Oiso N, Iba Y, Kawara S, et al. Halo phenomenon in neurofibromas and generalized vitiligo in a patient with neurofibromatosis type 1. Clin Exp Dermatol 2007 ; 32 : 207-8.
 
15) Oiso N, Amatsu A, Kawara S, et al. Pigmentary mosaicism with hyperpigmented streaks on the palmoplantar lesion associated with balanced X ; autosome translocations t (X ; 9) (p11.21 ; q34.1). J Eur Acad Dermatol Venereol 2009 ; 23 : 359-61.
PubMed
P.227 掲載の参考文献
1) 加藤裕史, 新谷洋一, 渡辺正一, ほか. 尋常性白範に対する1ミリミニグラフト療法の検討. 日皮会誌 2008 ; 118 : 2211-7.
 
2) 森田明理. ナローバンドUVB療法. 森田明理, ほか編. 1冊でわかる光皮膚科-皮膚科医に必須のphotodermatology. 東京 : 文光堂 ; 2008. pp176-85.
 
3) Krutmann J, Morita A. Therapeutic photomedicine phototherapy. In : Freedberg IM, et al, editors. 6th ed. Fitzpatrick's Dermatology in General Medicine. New York : McGraw-Hill : 2007. pp2243-9.
 
4) 前田晃, 森田明理. その他の光線療法. 森田明理, ほか編. 1冊でわかる光皮膚科-皮膚科医に必須のphotodermatology. 東京 : 文光堂 ; 2008. pp192-5.
 
5) Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band UVB radiation therapy. J Am Acad Dermatol 2000 ; 42 : 245-53.
PubMed
6) Taieb A, Picardo M. Vitiligo. N Engl J Med 2009 ; 360 : 160-9.
PubMed
7) Hanafusa T, Yamaguchi Y, Nakamura M, et al. Establishment of suction blister roof grafting by injection of local anesthesia beneath the epidermis : less painful and more rapid formation of blister. J Dermatol Sci 2008 ; 50 : 243-7.
PubMed
P.233 掲載の参考文献
1) Uno K, Nakamura K, Goto T, et al. Longitudinally excited N2 lasers without highvoltage switches. Rev Sci Instrum 2008 ; 79 : 063107.
PubMed
P.238 掲載の参考文献
1) Ohshiro T. High reactive-level laser treatment (HLLT) and low reactive-level laser therapy (LLLT) in dermatology. Photomed Photobio 1994 ; 16 : 123-6.
 
2) 大城俊夫. レーザーと生体反応. 渥美和彦, ほか編. 皮膚科・形成外科医のためのレーザー治療. 東京 : メジカルビュー社 ; 2000. pp45-55.
 
3) Mester E, Szende B, Gartner P. The effects of laser beams on the growth of hair in mice. Radiobiol Radiother 1968 ; 9 : 621-6.
PubMed
4) Mester E. Laser application in promoting of wound healing. In : Lasers in Medicine. Koebner HK, editor. Chichester : John Wiley & Sons ; 1980. pp190-213.
 
5) Kami T, Yoshimura Y, Nakajima T, et al. Effects of low-power diode lasers on flap survival. Ann Plast Surg 1985 ; 14 : 278-83.
PubMed
6) 久保田潤一郎, 大城俊夫, 藤野豊美. Gallium Alminium Arsenide半導体レーザーの皮弁に対する効果. 日レ会誌 1985 ; 5 : 417-20.
 
7) 岡田武史, 高橋克郎, 尾上泰彦, ほか. レーザーによる鍼治療 : Laser Acupuncture. 日レ会誌 1980 ; 1 : 47-50.
 
8) Moore KC, Hira N, Kumar PS, et al. A double blind crossover trial of low level laser therapy in the treatment of post herpatic neuralgia. Laser Therapy 1988 ; Pilot Issue : 7-10.
 
9) Morita H, Kohno J, Tanaka S, et al. Clinical application of GaAlAs 830 nm diode laser for atopic dermatitis. Laser Therapy 1993 ; 5 : 75-8.
 
10) Ohshiro T, Maeda T. Application of 830 nm diode laser LLLT as successful adjunctive therapy of hypertrophic scars and keoids. Laser Therapy 1992 ; 4 : 155-68.
 
11) Sasaki K, Ohshiro T. Role of low reactive level laser therapy (LLLT) in the treatment of acquired and cicatrical vitiligo. Laser Therapy 1989 ; 1 : 141-6.
 
P.241 掲載の参考文献
1) 坪井良治, 伊藤正俊, 伊藤裕喜, ほか. 白斑患者に対するメーキャップ化粧品の有用性の検討. 皮膚の科学 2006 ; 5 : 72-80.
 
2) Tanioka M, Yamamoto Y, Kato M, et al. Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol 2010 ; 9 : 72-5.
PubMed
3) Sagehashi Y, Ito A, Ohtake T, et al. Therapy makeup improves quality of life of patients with skin diseases-covering foundations created by integration of medical and beauty care for severe skin color problems. IFSCC Magazine 2008 ; 11 : 11-8.
 
P.244 掲載の参考文献
1) Alikhan A, Felsten LM, Daly M, et al. Vitiligo : a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011 ; 65 : 473-91.
PubMed
2) 堀川達弥, 永井宏. 尋常性白斑. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp172-81.
 
3) Lu T, Gao T, Wang A, et al. Vitiligo prevalence study in Shaanxi Province, China. Int J Dermatol 2007 ; 46 : 47-51.
 
4) 古賀道之. 尋常性白斑. 皮膚臨床 2001 ; 43 : 39-45.
 
5) Ezzedine K, Gauthier Y, Leaute-Lebreze C, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo) : a retrospective case series of 19 patients. J Am Acad Dermatol 2011 ; 65 : 965-71.
 
6) Hann S. Clinical features of segmental vitiligo. In : Hann S, et al, editors. Vitiligo. Boston : Blackwell Science ; 2000. pp49-60.
 
7) Gauthier Y, Cario-Andere M, Lepreux S, et al. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003 ; 148 : 95-101.
 
8) Spritz RA. Six decades of vitiligo genetics : genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 2012 ; 132 : 268-73.
PubMed
9) Taieb A, Morice-Picard F, Jouary T, et al. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism : implication for common non-segmental vitiligo. Pigment Cell Melanoma Res 2008 ; 21 : 646-52.
PubMed
10) Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011 ; 6 : e18907.
 
11) Papadopoulos L, Bor R, Legg C, et al. Impact of life events on the onset of vitiligo in adults : preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol 1998 ; 23 : 243-8.
PubMed
12) Gauthier Y, Cario-Andere M, Lepreux S, et al. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003 ; 148 : 95-101.
 
P.250 掲載の参考文献
1) 堀川達弥. 職業・環境物質による色素脱失. 宮地良樹, ほか編. 皮膚科診療プラクティス 20. Environmental Dermatology-環境・職業からみた皮膚疾患. 東京 : 文光堂 ; 2007. pp191-4.
 
2) 早川律子, 杉浦真理子. 化学物質による色素脱失. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp198-200.
 
3) Miyamoto L, Taylor JS. Chemical leukoderma. In : Hann SK, et al, editors. Vitiligo. Boston : Blackwell Science ; 2000. pp269-80.
 
4) Hariharan V, Klarquist J, Reust MJ, et al. Monobenzyl ether of hydroquinone and tertiary butyl phenol activate markedly different physiological responses in melanocytes : relevance to skin depigmentation. J Invest Dermatol 2010 ; 130 : 211-20.
PubMed
5) Le Poole IC, Yang F, Brown TL, et al. Altered gene expression in melanocytes exposed to 4-tertiary butyl phenol (4-TBP) : upregulation of the A2b adenosine receptor 1. J Invest Dermatol 1999 ; 113 : 725-31.
PubMed
6) Kroll TM, Bommiasamy H, Boissy RE, et al. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing : relevance to vitiligo. J Invest Dermatol 2005 ; 124 : 798-806.
PubMed
7) 中村好貴, 根本圭, 横山恵美, ほか. プレミネント (配合中のヒドロクロロチアジド) による光線性白斑黒皮症の1例. 西日皮膚 2011 ; 73 : 482-5.
 
8) 小林信彦. 光線性白斑黒皮症. 玉置邦彦, ほか編. 最新皮膚科学大系 8. 色素異常症. 東京 : 中山書店 ; 2002. pp94-6.
 
P.254 掲載の参考文献
1) Kopf AW, Morrill SO, Silberbara I. Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965 ; 92 : 14-35.
PubMed
2) Wayte OM, Helwig EB. Halo nevi. Cancer 1968 ; 22 : 69-90.
 
3) Larsson PA, Liden S. Prevalence of skin diseases among adolescents 12-16 years of age. Acta Derm Venereol 1980 ; 60 : 415-23.
PubMed
4) Copeman PW, Lewis MG, Phillips TM, et al. Immunological associations of the halo naevus with cutaneous malignant melanoma. Br J Dermatol 1973 ; 88 : 127-37.
PubMed
5) Berman B, Shaieb AM, France DS, et al. Halo giant congenital melanocytic nevus : in vitro immunologic studies. J Am Acad Dermatol 1988 ; 19 : 954-60.
 
6) Baranda L, Torres-Alvarez B, Moncada B, et al. Presence of activated lymphocytes in the peripheral blood of patients with halo nevi. J Am Acad Dermatol 1999 ; 41 : 567-72.
PubMed
7) Musette P, Bachelez H, Flageul B, et al. Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol 1999 ; 162 : 1789-94.
PubMed
8) van Geel N, Vandenhaute S, Speeckaert R, et al. Prognostic value and clinical significance of halo naevi regarding vitiligo. Br J Dermatol 2011 ; 164 : 743-9.
PubMed
9) 印南雅子, 古賀道之. サットン白斑の自然経過と中心部黒子切除の要否についての臨床的検討. 日皮会誌 1995 ; 105 : 957-62.
 
10) Frank SB, Cohen HJ. The halo nevus. Arch Dermatol 1964 ; 89 : 367-73.
PubMed
11) Gauthier Y, Surleve-Bazeille JE, Gauthier O, et al. Ultrastructure of halo nevi. J Cutan Pathol 1975 ; 2 : 71-81.
PubMed
P.259 掲載の参考文献
1) Speeckaert R, van Geel N, Vermaelen KV, et al. Immune reactions in benign and malignant melanocytic lesions : lessons for immunotherapy. Pigment Cell Melanoma Res 2010 ; 24 : 334-44.
PubMed
1) Richards JM, Mehta N, Ramming K, et al. Sequential chemotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992 ; 10 : 1338-43.
PubMed
2) Le Gal FA, Avril MF, Bosq J, et al. Direct evidence to support the role of antigenspecific CD8 (+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001 ; 117 : 1464-70.
PubMed
3) Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients : results from a single-institution hospital-based observational cohort study. Ann Oncol 2010 ; 21 : 409-12.
PubMed
4) Cui J, Bystrryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995 ; 131 : 314-8.
 
5) Hartmann A, Bedenk C, Keikavoussi P, et al. Vitiligo and melanoma-associated hypopigmentation (MAH) : shared and dicsriminative features. J Dtsch Dermatol Ges 2008 ; 6 : 1053-9.
PubMed
6) Kiecker F, Hofmann M, Sterry W, et al. Vitiligo-like depigmentation as a presenting sign of metastatic melanoma. J Eur Acad Dermatol Venereol 2006 ; 20 : 1135-7.
PubMed
P.262 掲載の参考文献
1) Ito M, Liu Y, Nguyen J, et al. Stem cells in the hair follicle bulge contribute to wound healing but not to homeostasis of the epidermis. Nat Med 2005 ; 11 : 1351-4.
 
2) Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentaion of vitiligo. J Invest Dermatol 1991 ; 97 : 410-6.
 
3) Parsad D, Pandhi R, Dogra S, et al. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004 ; 50 : 63-7.
PubMed
4) Montagna W, Chase HB. Histology and cytochemistry of human skin. Am J Anat 1956 ; 99 : 415-46.
PubMed
5) Staricco RG. Amelanotic melanocytes in the outer root sheeth of the human hair follicle. J Invest Dermatol 1959 ; 33 : 295-7.
 
6) Staricco RG. Mechanism of migration of the melanocytes from the hair follicle into the epidermis following dermabrasion. J Invest Dermatol 1961 ; 36 : 99-104.
 
7) Staricco RG. Activity of amelanotic melanocytes in the outer root sheeth of the hair follicle following ultraviolet exposure. J Invest Dermatol 1962 ; 39 : 163.
 
8) Horikawa Y, Norris DA, Johnson TW, et al. DOPA-negative melanocytes in the outer root sheath of human hair follicles express premelanosomal antigens but not a melanosomal antigen or the melanosome-associated glycoproteins tyrosinase, TRP-1, and TRP-2. J Invest Dermatol 1996 ; 106 : 28-35.
PubMed
9) Narisawa Y, Kohda H, Tanaka T. Three-dimensional demonstration of melanocyte distribution of human hair follicles : special reference to the bulge area. Acta Derm Venereol 1997 ; 77 : 97-101.
 
10) Ortonne JP, MacDonald DM, Micoud A, et al. PUVA-induced repigmentation of vitiligo : a histocjemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979 ; 101 : 1-12.
PubMed
11) Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991 ; 97 : 410-6.
PubMed
12) Cotsarelis G, Sun TT, Lavker RM, et al. Label-retaining cells reside in the bulge area of pilosebaceous unit : implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 1990 ; 61 : 1329-37.
PubMed
13) Oshima H, Rochat A, Kedzia C, et al. Morphogenesis and renewal of hair follicles from adult multipotent stem cells. Cell 2001 ; 104 : 233-45.
PubMed
14) Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of niche in melanocyte stem-cell fate determination. Nature 2002 ; 416 : 854-60.
PubMed
15) Okura M, Maeda H, Nishikawa S, et al. Effects of monoclonal anti-c-kit antibody (ACK2) on melanocytes in newborn mice. J Invest Dermatol 1995 ; 105 : 322-8.
 
16) Kunisada T, Lu SZ, Yoshida H, et al. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 1998 ; 187 : 1565-73.
PubMed
17) Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010 ; 362 : 1686-97.
PubMed
18) Spritz RA. Six decades of vitiligo genetics : genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 2012 ; 132 : 268-73.
PubMed
19) Oiso N, Suzuki T, Fukai K, et al. Nonsegmental vitiligo and autoimmune mechanism. Dermatol Res Pract 2011 ; 2011 : 518090.
PubMed
20) Cui J, Arita Y, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Research 1995 ; 8 : 53-9.
PubMed
21) Fujisaki J, Wu J, Carlson AL, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 2011 ; 474 : 216-9.
 
22) Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 2008 ; 159 : 1077-85.
PubMed
P.269 掲載の参考文献
1) Dell'Anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006 ; 19 : 406-11.
 
2) Dammak I, Boudaya S, Abdallah FB, et al. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol 2009 ; 48 : 476-80.
 
3) Dell'Anna ML, Ottaviani M, Albanesi V, et al. Membrane lipid alterations as a possible basis for melanocyte degeneration in vitiligo. J Invest Dermatol 2007 ; 127 : 1226-33.
PubMed
4) Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of aging. Nature 2000 ; 408 : 239-47.
PubMed
5) Bhawan J, Bhutani LK. Keratinocyte damage in vitiligo. J Cutan Pathol 1983 ; 10 : 207-12.
PubMed
6) Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000 ; 191 : 407-16.
 
7) Maresca V, Roccella M, Roccella F, et al. Increased sensitivity to peroxide agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997 ; 109 : 310-3.
PubMed
8) Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991 ; 97 : 1081-5.
PubMed
9) Liu L, Li C, Gao J, et al. Promoter variant in the catalase gene is associated with vitiligo in Chinese people. J Invest Dermatol 2010 ; 130 : 2647-53.
 
10) Thorneby-Andersson K, Sterner D, Hansson C. Tyrosinase-mediated formation of reactive quinine from the depigmenting agents, 4-tert-butylphenol and 4-tert-butylcatechol. Pigment Cell Res 2000 ; 13 : 33-8.
 
11) Yang F, Boissy RE. Effects of 4-tertiary butylphenol (4-TBP) on the tyrosinase activity in human melanocytes. Pigment Cell Res 1999 ; 12 : 237-45.
PubMed
12) Shalbaf M, Gibbons NCJ, Wood JM, et al. Presence of epidermal allantoin further supports oxidative stress in vitiligo. Exp Dermatol 2008 ; 17 : 761-80.
PubMed
13) Picardo M, Passi S, Morrone A, et al. Antioxidant status in the blood of patients with active vitiligo. Pigment Cell Res 1994 ; 7 : 110-5.
PubMed
14) Namazi MR. Proton pump inhibitors may trigger vitiligo by rendering melanocytes prone to appotosis. Br J Dermatol 2008 ; 158 : 844-5.
 
15) Schallreuter KU, Pittelkow MR, Wood JM. Free radical reduction by thioredoxin reductase at the surface of normal and vitiliginous keratinocytes. J Invest Dermatol 1986 ; 87 : 728-32.
PubMed
16) Lee SJ, Bai SK, Lee KS, et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I (kappa) B kinase-dependent NFkappaB activation. Mol Cells 2003 ; 16 : 97-105.
PubMed
17) Okamoto H, Horii K, Fujisawa A, et al. Oxidative deterioration of platinum nanoparticle and its prevention by palladium. Exp Dermatol 2012 ; 21 (Suppl 1) : 5-7.
 
18) Feng R, Lu Y, Bowman LL, et al. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 2005 ; 280 : 27888-95.
 
19) Alvarez-Suarez JM, Dekanski D, Ristic S, et al. Strawberry polyphenols attenuate ethanol-induced gastric lesions in rats by activation of antioxidant enzymes and attenuation of MDA increase. PLoS One 2011 ; 6 : e25878.
PubMed
20) Marsh TG, Straub RK, Villalobos F, et al. Soy protein supports cardiovascular health by downregulating hydroxymethylglutaryl-coenzyme A reductase and sterol regulatory element-binding protein-2 and increasing antioxidant enzyme activity in rats with dextran sodium sulfate-induced mild systemic inflammation. Nutr Res 2011 ; 31 : 922-8.
PubMed
21) Sun B, Sun GB, Xiao J, et al. Isorhamnetin inhibits H2O2-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation. J Cell Biochem 2012 ; 113 : 473-85.
PubMed
22) Schallreuter KU, Kruger C, Wurfel BA, et al. From basic research to the bedside : efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 2008 ; 47 : 743-53.
 
23) Sanclemente G, Garcia JJ, Zuleta JJ, et al. A double-blind, randomized trial of 0.05 % betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008 ; 22 : 1359-64.
 
24) Elgoweini M, Nour El Din N. Response of vitiligo to narrowband ultraviolet B and oral antioxidants. J Clin Pharmacol 2009 ; 49 : 852-5.
PubMed
P.274 掲載の参考文献
1) 片山一朗. 厚生労働省科学研究費補助金 難治性疾患克服研究事業 白斑の診断基準及び治療指針の確立 : 平成21年度総括・分担研究報告書. 2010.
 
2) Arca E, Tastan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006 ; 33 : 338-43.
PubMed
3) Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006 ; 20 : 269-73.
PubMed
4) Ermis O, Alpsoy E, Cetin L, et al. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebocontrolled double-blind study. Br J Dermatol 2001 ; 145 : 472-5.
PubMed
5) Katayama I, Ashida M, Maeda A, et al. Open trial of topical tacalcitol [1 alpha 24 (OH)2D3] and solar irradiation for vitiligo vulgaris : upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 2003 ; 13 : 372-6.
PubMed
6) 種村篤, 高橋彩, 上木裕理子, ほか. 尋常性白斑に対する活性型ビタミンD3外用と紫外線照射併用療法の有効性についての検討. 皮膚の科学 2011 ; 10 : 485-93.
 
7) Miller AJ, Tsao H. New insight into pigmentary pathways and skin cancer. Br J Dermatol 2010 ; 162 : 22-8.
PubMed

書評

最近チェックした商品履歴

Loading...